Paper5118468
Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.
Medoff G and 2 others. Proc Soc Exp Biol Med, 1971. Cited by 216 papers, by iCite.
Cite this record
ConductScience Library. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Papers, record 5118468. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5118468
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amphotericin B | Major topic |
| Antifungal Agents | Major topic |
| Cytosine | Major topic |
| Drug Synergism | Major topic |
| Candida | |
| Cell Count | |
| Cells, Cultured | |
| Cryptococcus | |
| Drug Resistance, Microbial | |
| Fluorine | |
| Saccharomyces |
Source PubMed
Cited by52
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 216 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40693795 | Breaking down biofilms across critical priority fungal pathogens: proteomics and computational innovation for mechanistic insights and new target discovery. | mBio | 2025 | https://conductscience.org/library/papers/40693795 | PubMed |
| 34151414 | Drug repurposing strategies in the development of potential antifungal agents. | Appl Microbiol Biotechnol | 2021 | https://conductscience.org/library/papers/34151414 | PubMed |
| 28205003 | Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation. | Pharm Res | 2017 | https://conductscience.org/library/papers/28205003 | PubMed |
| 25026870 | Yeast central nervous system infection in a critically ill patient: a case report. | J Med Case Rep | 2014 | https://conductscience.org/library/papers/25026870 | PubMed |
| 24595533 | Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. | Clin Pharmacokinet | 2014 | https://conductscience.org/library/papers/24595533 | PubMed |
| 17043122 | Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17043122 | PubMed |
| 16377675 | Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/16377675 | PubMed |
| 16033288 | Antifungal combination therapy: clinical potential. | Drugs | 2005 | https://conductscience.org/library/papers/16033288 | PubMed |
| 15830474 | In vitro and in vivo activity of 5-fluorocytosine on Acanthamoeba. | Antimicrob Agents Chemother | 1974 | https://conductscience.org/library/papers/15830474 | PubMed |
| 15015031 | Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. | Eur J Clin Microbiol Infect Dis | 2004 | https://conductscience.org/library/papers/15015031 | PubMed |
| 14982754 | Combination antifungal therapy. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/14982754 | PubMed |
| 10949601 | New antifungal therapy in ophthalmology. | Trans Am Ophthalmol Soc | 1973 | https://conductscience.org/library/papers/10949601 | PubMed |
| 10515900 | Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. | Clin Microbiol Rev | 1999 | https://conductscience.org/library/papers/10515900 | PubMed |
| 8964037 | History of medical mycology in the united states. | Clin Microbiol Rev | 1996 | https://conductscience.org/library/papers/8964037 | PubMed |
| 8585726 | In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/8585726 | PubMed |
| 8573294 | Lipid formulations of amphotericin B. Less toxicity but at what economic cost? | Drug Saf | 1995 | https://conductscience.org/library/papers/8573294 | PubMed |
| 7385824 | Management of central nervous system cryptococcosis. | West J Med | 1980 | https://conductscience.org/library/papers/7385824 | PubMed |
| 6301590 | Therapy of fungal infections. | Bull N Y Acad Med | 1982 | https://conductscience.org/library/papers/6301590 | PubMed |
| 6299182 | Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6299182 | PubMed |
| 6295266 | Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/6295266 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/5118468
GET https://conductscience.org/api/papers/v1/5118468/cited_by?page=2